Article
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
Clinical lymphoma, myeloma & leukemia - 1 Mar 2015
Pemmaraju Naveen, Kantarjian Hagop, Kadia Tapan, Cortes Jorge, Borthakur Gautam, Newberry Kate, Garcia-Manero Guillermo, Ravandi Farhad, Jabbour Elias, Dellasala Sara, Pierce Sherry, Verstovsek Srdan
Abstract excerpt
BACKGROUND: Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis. PATIENTS AND METHODS: We conducted a single-center phase I/II clinical study testing 3 dose levels (50 mg b.i.d. [n = 4], 100 mg b.i.d. [n = 5], and 200 mg b.i.d. [n = 18]). We enrolled 27 patients older than 14 years with relapsed or refractory acute myeloid leukemia (n = 26) or acute...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.